过氧化氢(Hydrogen Peroxide) - 在研适应症：消毒剂，伤口感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

ESKATA、ESKERIELE、hydrogen peroxide

+ [2]

靶点-

作用方式

刺激剂

作用机制

细胞凋亡刺激剂

治疗领域

感染其他疾病

在研适应症

消毒剂伤口感染

非在研适应症

寻常痤疮黑色丘疹性皮病脂溢性角化病+ [2]

原研机构

天津市东方广诚医药化工有限公司

在研机构

天津市东方广诚医药化工有限公司Ebisu Yakuhin Kako KK

非在研机构

Cipher Pharmaceuticals, Inc.

Aclaris Therapeutics, Inc.JDC Tech Co. Ltd.

权益机构

Cipher Pharmaceuticals, Inc.

Aclaris Therapeutics, Inc.

最高研发阶段批准上市

首次获批日期

中国 (1981-01-01),

伤口感染

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式H2O2

InChIKeyMHAJPDPJQMAIIY-UHFFFAOYSA-N

CAS号7722-84-1

关联

101

项与过氧化氢相关的临床试验

NCT06884813

/ RecruitingN/AIIT

Clinical Evaluation of a Single-Shade, Color-Adjusting Composite Resin Following In-Office Dental Bleaching: A Randomized Clinical Trial

One challenge faced by dental professionals is that, unlike natural tooth structure, composite restorations do not lighten when exposed to bleaching agents. As a result, functional restorations may need replacement after bleaching to match the newly whitened teeth. However, replacing a composite restoration can lead to unnecessary removal of tooth structure, potentially weakening the tooth and increasing its susceptibility to further iatrogenic damage. This study will investigate the ability of Omnichroma restorations to shade-match tooth structure after bleaching.
The null hypotheses will be:
1. Single-shade RBC will not exhibit similar shade and optical behavior to conventional RBC across all anterior restorations following bleaching.
2. Patient satisfaction regarding color blending between the restoration and tooth structure will not differ according to the type of material used.
3. Dentist satisfaction regarding color blending between the restoration and tooth structure will not differ according to the type of material used.

开始日期2025-03-10

申办/合作机构

King Abdullah University Hospital

RBR-2y7jf2c

/ Not yet recruitingN/AIIT

Efiicacy of brush-on vs. tray-delivery at-home bleaching with 6% hydrogen peroxide: A randomized, single-blind, split-mouth controlled trial

开始日期2025-02-10

申办/合作机构

Universidade Estadual de Ponta Grossa

[+1]

RBR-45bk3sw

/ Not yet recruitingN/AIIT

Efficacy of in-office Bleaching using 35% Self-mixed Hydrogen Peroxide reducing application time: a single-blind randomized clinical trial

开始日期2024-12-15

申办/合作机构

Universidade Estadual de Ponta Grossa

[+1]

100 项与过氧化氢相关的临床结果

登录后查看更多信息

100 项与过氧化氢相关的转化医学

登录后查看更多信息

100 项与过氧化氢相关的专利（医药）

登录后查看更多信息

193,446

项与过氧化氢相关的文献（医药）

2025-12-31·Plant Signaling & Behavior

Expression characteristics of CsESA1 in citrus and analysis of its interacting protein

Article

作者: Wei, Wei ; Wang, Huiying ; Zuo, Jiaqi ; He, Xiao ; He, Qing ; Han, Ziyue

The most damaging disease affecting citrus globally is Huanglongbing (HLB), primarily attributed to the infection by 'Candidatus Liberibacter asiaticus' (CaLas). Based on comparative transcriptome data, two cellulose synthase (CESA) genes responsive to CaLas infection induction were screened, and one gene cloned with higher differential expression level was selected and named CsCESA1. we verified the interaction between CsCESA1 and citrus exopolysaccharide 2 (CsEPS2) proteins. Subcellular localization in tobacco indicated that both CsCESA1 and CsEPS2 proteins are primarily located in the nucleus and cytoplasm. RT-qPCR analysis indicated that the expression levels of CsCESA1 and CsEPS2 were associated with variety tolerance, tissue site, and symptom development. Furthermore, we generated CsCESA1 and CsEPS2 silencing plants and obtained CsCESA1 and CsEPS2 silencing and overexpressing hairy roots. The analysis of hormone content and gene expression also showed that CsCESA1 and CsEPS2 are involved in transcriptional regulation of genes involved in systemic acquired resistance (SAR) response. In conclusion, our results suggested that CsCESA1 and CsEPS2 could serve as potential resistance genes for HLB disease, offering insights into the plant's defense mechanisms against HLB.

2025-12-31·Environmental Pollutants and Bioavailability

Application of a multi-metal tolerant plant growth-promoting Bacillus sp. S3 for remediation of Cu and Pb co-contaminated soil and enhancement of pakchoi ( Brassica chinensis L) performance

作者: Li, Jiaokun ; Zhou, Han ; Ran, Maodi ; Fu, Jun ; Shi, Ying ; Jiao, Ying

This study investigates the potential of the multi-metal tolerant bacterium Bacillus sp.S3 to remediate Pb- and Cu-contaminated soils while enhancing the growth of pakchoi (Brassica chinensis L.).Our findings demonstrate that inoculation with Bacillus sp.S3 significantly increased pakchoi biomass, leaf chlorophyll content, and antioxidant levels, while effectively reducing oxidative stress indicators.Addnl, Bacillus sp.S3 markedly improved soil enzyme activities and enhanced Pb immobilization in the soil, thereby limiting the uptake of Pb and Cu in pakchoi leaves.These results underscore the ability of Bacillus sp.S3 to simultaneously mitigate heavy metal toxicity, support plant growth, and restore soil health, offering a sustainable solution for the remediation of metal-polluted soils and the production of safer crops.

2025-12-31·Virulence

Decarboxylase mediated oxalic acid metabolism is important to antioxidation and detoxification rather than pathogenicity in Magnaporthe oryzae

Article

作者: He, Zhengquan ; Wei, Yi ; Fan, Xiaoning ; Zhang, Shihong ; Liu, Chang ; Dang, Yuejia ; Hu, Yan ; Batool, Wajjiha

Oxalic acid (OA), an essential pathogenic factor, has been identified in several plant pathogens, and researchers are currently pursuing studies on interference with OA metabolism as a treatment for related diseases. However, the metabolic route in Magnaporthe oryzae remains unknown. In this study, we describe D-erythroascorbic acid-mediated OA synthesis and its metabolic and clearance pathways in rice blast fungus. By knocking out the D-arabino-1,4-lactone oxidase gene (Moalo1), one-third of oxalic acid remained in M. oryzae, indicating a main pathway for oxalic acid production. M. oryzae OxdC (MoOxdC) is an oxalate decarboxylase that appears to play a role in relieving oxalic acid toxicity. Loss of Mooxdc does not affect mycelial growth, conidiophore development, or appressorium formation in M. oryzae; however, the antioxidant and pathogenic abilities of the mutant were enhanced. This is owing to Mooxdc deletion upregulated a series of OA metabolic genes, including the oxalate oxidase gene (Mooxo) and Moalo1, as well as both OA transporter genes. Simultaneously, as feedback to the tricarboxylic acid (TCA) cycle, the decrease of formic acid in ΔMooxdc leads to the reduction of acetyl-CoA content, and two genes involved in the β-oxidation of fatty acids were also upregulated, which enhanced the fatty acid metabolism of the ΔMooxdc. Overall, this work reveals the role of OA in M. oryzae. We found that OA metabolism was mainly involved in the growth and development of M. oryzae, OA as a byproduct of D-erythroascorbic acid after removing H₂O₂, the OA-associated pathway ensures the TCA process and ATP supply.

114

项与过氧化氢相关的新闻（医药）

2025-08-11

·GlobeNewswire-Health Care

TOMI Environmental Solutions Secures Order from ARES Distribution

FREDERICK, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that it has received a significant order from ARES Distribution, a global distributor of scientific and medical equipment and products. This is the fourth order the Company has received for its recently launched SteraMist Integration System (SIS) platform of products. The order is for a biomedical research university located in Coral Gables, Florida, and is fast-tracked with an anticipated delivery set for late 2025. “Securing this order is a testament to our commitment to innovation and collaboration within the sterilization technology space,” said Elissa J. Shane, Chief Operating Officer of TOMI Environmental Solutions. “Each new project contributes valuable insights into the workflow optimization of our SteraMist iHP technology and its automation capabilities. Our partnership with ARES Distribution has been invaluable, and we are excited to continue developing and providing cutting-edge solutions that enhance safety and efficiency in critical environments.” “We are pleased with the traction that our recently launched SIS platform of products is getting in the marketplace,” commented Elissa J. Shane. “Contamination control and disinfection are critical in research and healthcare settings, and we look forward to continuing to collaborate with a broadening base of manufacturers committed to enhancing quality and safety standards.” TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments. For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s partnership with ARES Distribution and TOMI’s products to serve life science and university sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT:John Nesbett/Rosalyn ChristianIMS Investor Relationstomi@imsinvestorrelations.com

2025-08-06

·药物分子设计

齐鲁工大肖静等运用大肠杆菌CRISPR转座增产亮氨酸

L-亮氨酸是哺乳动物不能合成的一种必需氨基酸，在各个领域有着广泛的应用。然而，L-亮氨酸的大规模生产仍然面临菌株和工艺优化方面的各种挑战。近日，来自齐鲁工业大学的肖静等人在《Fermentation》期刊上发表文章“Enhanced L-Leucine Production in Escherichia coli via CRISPR-Associated Transposase Genome Engineering”，采用CRISPR转座酶整合和质粒双增强策略增强L-亮氨酸代谢途径。研究以自家产L-亮氨酸的大肠杆菌A211为初始菌株，利用CRISPR转座酶在多拷贝IS1位点分别整合异丙基苹果酸合酶基因leuA、异丙基苹果酸异构酶基因leuCD、异丙基苹果酸脱氢酶基因leuB和亮氨酸脱氢酶基因bcd，并进一步分别在其基础上用质粒过表达剩下三个基因获得了4株工程菌株A101（基因组整合leuA+质粒过表达 leuB 、 leuCD 和 bcd，剩下的菌株依次类推）、B201、CD301和bcd401。对四个菌株进行转录水平分析，结果显示工程菌株CD301 的总体基因表达水平最高，其次是大肠杆菌 A101。发酵结果显示，CD301的L-亮氨酸滴度最高（0.57±0.01 g/L），较亲本菌株提高了97%。进一步采用单因素优化和响应面法（温度、C/N比、接种量等变量）对大肠杆菌CD301发酵条件进行优化，L-亮氨酸滴度为0.89±0.03 g/L，较优化前提高了56.1%。总的来说，该研究利用CRISPR转座酶进行基因组整合结合质粒过表达成功提高了亲本大肠杆菌的L-亮氨酸产量。（周晓杰摘译）

基因疗法临床研究临床结果

2025-07-16

·GlobeNewswire-Health Care

TOMI Environmental Solutions Advances New Product, SteraMist Integration System – Standalone (SIS-SA)

FREDERICK, Md., July 16, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the successful first installation of its new SteraMist Integration System – Standalone (SIS-SA) in the life sciences sector, beginning with pharmaceutical isolator market. The life science sterility testing market is experiencing significant growth, driven by increased demand for pharmaceutical and biotechnology products, stricter regulatory standards, and advancements in testing methodologies. This growth reflects the critical need to ensure the safety and efficacy of sterile products across the pharmaceutical, medical device, and biopharmaceutical sectors. As life sciences organizations strive to meet stringent regulatory requirements and produce sterile drugs, the role of aseptic isolators becomes increasingly critical. A leading pharmaceutical drug Contract Development and Manufacturing Organization (CDMO) company first implemented SteraMist iHP technology in 2023. Having previously purchased several Surface Unit handheld direct spray systems, they further invested in the first quarter of this year by acquiring the new SIS-SA, complete with a 90-degree applicator, to retrofit an existing isolator in collaboration with a prominent isolator manufacturing company. The successful recent installation and validation of this iHP isolator is the first completed deployment of the SIS-SA, part of the SteraMist Integrated Systems (SIS) launched in the second half of last year. TOMI is actively working on additional projects of this type, with installations scheduled for later this year Dr. Halden Shane, CEO and Chairman of the Board of TOMI Environmental Solutions, Inc., states “The successful installation of our first SIS-SA system marks an important achievement and is a milestone in our strategy to expand our footprint in the life sciences industry. As demand grows for safe, sterile drug manufacturing environments, our SteraMist technology continues to demonstrate its value. With the life science sterility testing market expected to grow to $3.4 billion by 2031 at a CAGR of 12.4%, we believe TOMI is well positioned to meet the evolving needs of life science manufacturers through innovative, scalable solutions like SIS-SA.” The Company expects to realize in excess of half a million dollars in revenue from the new SIS-SA product in fiscal 2025. TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments. For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to anticipated growth in the life science markets and TOMI’s products to serve life science sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT:John Nesbett/Rosalyn ChristianIMS Investor Relationstomi@imsinvestorrelations.com

并购

100 项与过氧化氢相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
脂溢性角化病	美国	Aclaris Therapeutics, Inc.	2017-12-14
消毒剂	日本	Ebisu Yakuhin Kako KK	1986-03-01
伤口感染	中国	天津市东方广诚医药化工有限公司	1981-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常痤疮	临床3期	美国	Aclaris Therapeutics, Inc.	2018-09-17
跖疣	临床3期	美国	Aclaris Therapeutics, Inc.	2018-09-13
黑色丘疹性皮病	临床2期	美国	Aclaris Therapeutics, Inc.	2017-06-26
可见病灶	临床2期	美国	Aclaris Therapeutics, Inc.	2017-06-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04659928 (CTgov)	临床4期	新型冠状病毒感染	41	High volume evacuation (HVE)+Hydrogen Peroxide (High Volume Evacuation (HVE) Suction Only and Hydrogen Peroxide)	顧築鹽範夢選蓋糧醖顧(鹹網餘觸壓壓網網鬱襯) = 鬱襯醖鏇築獵遞構網窪製鑰襯鬱鹽糧製製壓鏇 (衊鏇網鬱觸獵繭艱鹽網, 16.38) 更多	-	2025-07-08
				Extraoral vacuum aspirator (EVA)+Hydrogen Peroxide (HVE Suction and Extraoral Vacuum Aspirator (EVA) and Hydrogen Peroxide)	顧築鹽範夢選蓋糧醖顧(鹹網餘觸壓壓網網鬱襯) = 夢願醖夢願鑰蓋觸淵蓋製鑰襯鬱鹽糧製製壓鏇 (衊鏇網鬱觸獵繭艱鹽網, 155.43) 更多
ASTRO2024	N/A	直肠癌	-	Hydrogen Peroxide + Neoadjuvant Chemoradiotherapy	鑰網積鏇夢鏇齋夢鑰憲(繭鹽觸艱構簾糧顧衊願) = significantly more patients with grade 2 proctitis were observed in the IG (IG; 30%, HC; 0%; p<0.01) and 2 patients showed grade 2 hemorrhage in the IG but none in the HC 壓衊願鑰餘鹹淵遞鑰鏇 (餘繭齋淵觸廠艱鬱鏇蓋 ) 更多	-	2024-10-01
				Neoadjuvant Chemoradiotherapy
NCT03262701 (AHP, CTgov)	临床4期	慢性牙周炎	42	Hydrogen Peroxide (Hydrogen Peroxide Gel for 13weeks)	製範願艱獵窪簾鏇夢鑰(簾夢顧壓鏇壓齋鹽憲糧) = 網衊襯壓鏇獵襯糧廠憲積膚衊製壓膚鏇願遞糧 (鏇壓簾壓淵夢壓齋獵鹹, 0.16) 更多	-	2022-12-21
				Hydrogen Peroxide (Hydrogen Peroxide Gel for 26weeks)	製範願艱獵窪簾鏇夢鑰(簾夢顧壓鏇壓齋鹽憲糧) = 網蓋網餘顧淵醖廠廠遞積膚衊製壓膚鏇願遞糧 (鏇壓簾壓淵夢壓齋獵鹹, 0.05) 更多
NCT03691831 (CTgov)	临床3期	跖疣 \| 疣	502	Active (Active)	觸襯襯遞獵製鏇蓋壓壓 = 醖鬱構糧鏇獵淵膚鹽積壓遞窪範鏇網鹹顧齋鬱 (蓋齋淵選製鬱鏇淵衊鹽, 壓範襯鏇鹽膚鬱襯鹹願 ~ 憲壓鹹構觸壓繭鬱鏇願) 更多	-	2020-10-05
				Vehicle (Vehicle)	觸襯襯遞獵製鏇蓋壓壓 = 窪衊餘製淵鏇淵襯鬱遞壓遞窪範鏇網鹹顧齋鬱 (蓋齋淵選製鬱鏇淵衊鹽, 廠夢鹹鑰糧獵鏇壓鹹醖 ~ 鏇壓壓網觸網糧膚蓋窪) 更多
NCT03687372 (CTgov)	临床3期	跖疣 \| 疣	503	vehicle	襯餘範蓋獵醖繭鹹憲構(獵壓築網獵鑰鏇淵衊衊) = 鹹糧鏇餘鑰蓋鏇膚鹽蓋選膚鹽糧鹹範製選鹹醖 (顧淵壓顧憲憲構淵廠淵, 窪糧遞廠築糧簾鬱積窪 ~ 艱壓憲鹽齋鏇願餘蓋襯) 更多	-	2020-10-05
NCT03224598 (CTgov)	临床2期	黑色丘疹性皮病	39	A-101 Topical Solution 40% (No Medical Abrading)	襯壓壓構淵衊襯願糧膚(鏇齋醖憲選製顧鏇積簾) = 鏇齋壓餘夢獵夢顧憲淵鏇糧醖鬱淵齋簾選鏇網 (鑰蓋獵壓餘膚積願鬱糧, 0.52) 更多	-	2020-03-17
				A-101 Topical Solution 40% (Medically Abrading)	襯壓壓構淵衊襯願糧膚(鏇齋醖憲選製顧鏇積簾) = 衊遞鑰憲壓憲構廠繭夢鏇糧醖鬱淵齋簾選鏇網 (鑰蓋獵壓餘膚積願鬱糧, 0.90) 更多
NCT03487588 (SK-FAN, CTgov)	临床4期	脂溢性角化病	41	A-101 Topical Solution	範窪餘顧醖簾鹽構顧網(網憲範顧鹽遞構鹹鬱廠) = 鏇廠壓鑰鬱築築膚繭鑰築齋觸鹹積衊艱製醖餘 (餘蓋繭獵獵製衊壓壓獵, 0.62) 更多	-	2019-10-02
NCT03148691 (CTgov)	临床2期	脂溢性角化病	253	A-101 (Vehicle)	簾膚憲壓鏇選衊襯鬱製(網觸鏇獵繭網壓膚鬱齋) = 構艱積膚蓋繭鹽選鏇壓願憲醖鏇繭窪構鬱窪艱 (鏇觸衊觸鑰製醖鏇艱積, 10.4) 更多	-	2019-05-06
				A-101 (A-101 Low Dose)	簾膚憲壓鏇選衊襯鬱製(網觸鏇獵繭網壓膚鬱齋) = 襯鏇願製顧選構選鹽膚願憲醖鏇繭窪構鬱窪艱 (鏇觸衊觸鑰製醖鏇艱積, 36.74) 更多
NCT03210337 (CTgov)	临床2期	疣	157	A-101 Topical Solution (Active)	願衊鹹網襯壓繭築製選(遞選廠構鑰簾簾製簾鏇) = 願憲襯鹽築願糧衊遞鏇醖齋壓窪艱積鹽築繭鹹 (積獵顧顧範選窪齋網憲, 0.85) 更多	-	2019-05-01
				A-101 Vehicle Solution (Vehicle)	願衊鹹網襯壓繭築製選(遞選廠構鑰簾簾製簾鏇) = 膚繭襯窪鏇壓壓蓋鏇餘醖齋壓窪艱積鹽築繭鹹 (積獵顧顧範選窪齋網憲, 0.49) 更多